查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586051

癌症免疫治疗市场：按产品、功能和最终用户划分 - 全球预测 2025-2030

Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症免疫治疗市场价值为733.8亿美元，预计到2024年将达到773.9亿美元，复合年增长率为5.54%，预计到2030年将达到1071.1亿美元。

癌症免疫疗法是肿瘤学的一个突破性领域，它利用人体的免疫系统来对抗癌细胞，与化疗和放射线治疗等传统疗法相比，我们提供更有针对性的治疗方法。癌症免疫疗法的需求在于其延长存活期、提高疗效和减少副作用的潜力。癌症免疫疗法可应用于多种癌症类型，包括黑色素瘤、肺癌和白血病，并且对于患者特定的治疗计划至关重要。最终用途范围主要包括医院、癌症研究中心和专科诊所，可以在其中进行和监测这些治疗方法。

主要市场统计
基准年[2023] 733.8亿美元
预测年份 [2024] 773.9亿美元
预测年份 [2030] 1071.1亿美元
复合年增长率（%） 5.54%

生物技术的进步、癌症发生率的增加以及个人化医疗意识的增强是市场成长的主要驱动力。主要商机在于新型免疫疗法药物的开发、与现有治疗药物的联合使用以及拓展医疗基础设施发达的新兴市场。抓住这些机会的研究包括投资于研发、培养与生物技术公司的合作伙伴关係以及在潜力开拓的地区建立市场影响。

然而，它们面临着治疗成本高、监管途径复杂和潜在副作用等限制的挑战。此外，新治疗方法的临床试验和检验所需的时间较长也是限制市场的因素。创新对于克服这些障碍至关重要，联合治疗、患者选择的生物标记研究以及 CAR-T 细胞疗法等现成解决方案的开发等领域尤其有前景。

对改进给药方法和尽量减少免疫相关副作用的研究可能会进一步支持成长。市场动态是动态的，其特点是技术快速进步和竞争压力。因此，公司需要随时了解科学突破、监管变化和伙伴关係机会，以保持竞争力并优化其在这个变革性产业的成长策略。

市场动态：揭示快速发展的癌症免疫治疗市场的关键市场洞察

供需的动态交互作用正在改变癌症免疫治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球癌症患者数量增加
    • 先进抗癌药物的采用增加
    • 癌症治疗研发活动投资快速增加
  • 市场限制因素
    • 资本集中治疗和治疗
  • 市场机会
    • 药物开发过程中生物资讯学工具的广泛开发
    • 与癌症免疫疗法相关的临床试验增加
  • 市场挑战
    • 限制免疫反应的癌症併发症

波特五力：驾驭癌症免疫治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解癌症免疫治疗市场的外部影响

外部宏观环境因素在塑造癌症免疫治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解癌症免疫治疗市场的竞争格局

对癌症免疫治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵癌症免疫治疗市场供应商的绩效评估

FPNV定位矩阵是评估癌症免疫治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了癌症免疫治疗市场的成功之路

癌症免疫治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症患者的发生率正在上升
      • 扩大先进癌症治疗方法的引进
      • 癌症治疗研发活动投资快速增加
    • 抑制因素
      • 资本集中治疗和程序
    • 机会
      • 药物开发过程中生物资讯学工具的广泛开发
      • 癌症免疫治疗临床试验数量增加
    • 任务
      • 癌症併发症限制免疫反应
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症免疫治疗市场：副产品

  • 细胞疗法
    • 嵌合体抗原受体T细胞疗法
    • 树突状细胞
  • 查核点抑制剂
    • 细胞毒性T淋巴球相关蛋白4
    • 程序性死亡 1 和程序性死亡配体 1
  • 免疫调节剂
    • 粒细胞-巨噬细胞集落刺激因子
    • 干扰素
    • 白细胞介素
    • 溶瘤病毒
  • 单株抗体
    • 双特异性单株抗体
    • 结合单株抗体
    • 裸单株抗体
  • 疫苗
    • 预防性疫苗
    • 治疗性疫苗

第七章癌症免疫治疗市场：依功能分类

  • 乳癌
  • 大肠直肠癌
  • 头颈癌
  • 肺癌
  • 恶性黑色素瘤
  • 多发性骨髓瘤
  • 摄护腺癌

第八章癌症免疫治疗市场：依最终用户分类

  • 癌症研究组织
  • 诊所
  • 医院

第九章美洲癌症免疫治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区癌症免疫治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的癌症免疫治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amgen Inc.
  • AstraZeneca PLC
  • Avid Bioservices, Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • CH Boehringer Sohn AG & Ko. KG
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GSK PLC
  • Janssen Global Services, LLC
  • Merck & Co., Inc.
  • Novartis International AG
  • OSE Immunotherapeutics SA
  • Pfizer, Inc.
Product Code: MRR-4330CC794A6B

The Cancer Immunotherapy Market was valued at USD 73.38 billion in 2023, expected to reach USD 77.39 billion in 2024, and is projected to grow at a CAGR of 5.54%, to USD 107.11 billion by 2030.

Cancer immunotherapy, a groundbreaking area within oncology, leverages the body's immune system to combat cancer cells, offering a more targeted approach compared to traditional treatments such as chemotherapy and radiation. The necessity for cancer immunotherapy arises from its potential to provide prolonged survival rates, enhanced efficacy, and reduced side effects. Its applications span various cancer types, including melanoma, lung cancer, and leukemia, making it crucial for patient-specific treatment plans. The end-use scope primarily includes hospitals, cancer research centers, and specialty clinics where these therapies can be administered and monitored.

KEY MARKET STATISTICS
Base Year [2023] USD 73.38 billion
Estimated Year [2024] USD 77.39 billion
Forecast Year [2030] USD 107.11 billion
CAGR (%) 5.54%

Market growth is prominently driven by advancements in biotechnology, increasing prevalence of cancer, and rising awareness about personalized medicine. Key opportunities lie in the development of novel immunotherapeutic agents and combinations with existing therapies, as well as the expansion into emerging markets with improved healthcare infrastructures. Recommendations to seize these opportunities include investing in research and development, fostering collaborations with biotech firms, and establishing market presence in regions with untapped potential.

However, limitations such as high treatment costs, complex regulatory pathways, and potential adverse reactions pose challenges. The market is also constrained by the lengthy timeline necessary for clinical trials and validation of new treatments. Innovation can be pivotal in overcoming these barriers, with areas like combination therapies, biomarker research for patient selection, and development of off-the-shelf solutions like CAR-T cell therapy being particularly promising.

Research into improving delivery methods and minimizing immune-related adverse effects would further aid growth. The cancer immunotherapy market is dynamic, marked by rapid technological advances and competitive pressure. Thus, companies must stay abreast of scientific breakthroughs, regulatory changes, and partnership opportunities to maintain a competitive edge and optimize growth strategies within this transformative sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Immunotherapy Market

The Cancer Immunotherapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer patients worldwide
    • Increasing adoption of advanced cancer therapeutics
    • Surging investments in research and development activities of cancer treatment
  • Market Restraints
    • Capital intensive treatment and procedures
  • Market Opportunities
    • Extensive development of bioinformatics tools in drug development process
    • Growing number of clinical trials for cancer immunotherapy
  • Market Challenges
    • Complications in cancer limiting the immune response

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Immunotherapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Immunotherapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Immunotherapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Immunotherapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Immunotherapy Market

A detailed market share analysis in the Cancer Immunotherapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Immunotherapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Immunotherapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Immunotherapy Market

A strategic analysis of the Cancer Immunotherapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Avid Bioservices, Inc., Bayer AG, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GSK PLC, Janssen Global Services, LLC, Merck & Co., Inc., Novartis International AG, OSE Immunotherapeutics SA, and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Cell Therapies, Checkpoint Inhibitors, Immunomodulators, Monoclonal Antibodies, and Vaccines. The Cell Therapies is further studied across Chimeric Antigen Receptor T Cell Therapy and Dendritic Cells. The Checkpoint Inhibitors is further studied across Cytotoxic T-Lymphocyte-Associated Protein-4 and Programmed Death 1 & Programmed Death Ligand 1. The Immunomodulators is further studied across Granulocyte-Macrophage Colony-Stimulating Factor, Interferons, Interleukins, and Oncolytic Virus. The Monoclonal Antibodies is further studied across Bispecific Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Naked Monoclonal Antibodies. The Vaccines is further studied across Prophylactic Vaccines and Therapeutic Vaccines.
  • Based on Function, market is studied across Breast Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, Melanoma, Multiple Myeloma, and Prostate Cancer.
  • Based on End-User, market is studied across Cancer Research Institutes, Clinics, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer patients worldwide
      • 5.1.1.2. Increasing adoption of advanced cancer therapeutics
      • 5.1.1.3. Surging investments in research and development activities of cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Capital intensive treatment and procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Extensive development of bioinformatics tools in drug development process
      • 5.1.3.2. Growing number of clinical trials for cancer immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Complications in cancer limiting the immune response
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Immunotherapy Market, by Product

  • 6.1. Introduction
  • 6.2. Cell Therapies
    • 6.2.1. Chimeric Antigen Receptor T Cell Therapy
    • 6.2.2. Dendritic Cells
  • 6.3. Checkpoint Inhibitors
    • 6.3.1. Cytotoxic T-Lymphocyte-Associated Protein-4
    • 6.3.2. Programmed Death 1 & Programmed Death Ligand 1
  • 6.4. Immunomodulators
    • 6.4.1. Granulocyte-Macrophage Colony-Stimulating Factor
    • 6.4.2. Interferons
    • 6.4.3. Interleukins
    • 6.4.4. Oncolytic Virus
  • 6.5. Monoclonal Antibodies
    • 6.5.1. Bispecific Monoclonal Antibodies
    • 6.5.2. Conjugated Monoclonal Antibodies
    • 6.5.3. Naked Monoclonal Antibodies
  • 6.6. Vaccines
    • 6.6.1. Prophylactic Vaccines
    • 6.6.2. Therapeutic Vaccines

7. Cancer Immunotherapy Market, by Function

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Head & Neck Cancer
  • 7.5. Lung Cancer
  • 7.6. Melanoma
  • 7.7. Multiple Myeloma
  • 7.8. Prostate Cancer

8. Cancer Immunotherapy Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Research Institutes
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Cancer Immunotherapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Immunotherapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Immunotherapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. AstraZeneca PLC
  • 3. Avid Bioservices, Inc.
  • 4. Bayer AG
  • 5. Bristol-Myers Squibb
  • 6. C.H. Boehringer Sohn AG & Ko. KG
  • 7. ELI Lilly and Company
  • 8. F. Hoffmann-La Roche Ltd
  • 9. Gilead Sciences, Inc.
  • 10. GSK PLC
  • 11. Janssen Global Services, LLC
  • 12. Merck & Co., Inc.
  • 13. Novartis International AG
  • 14. OSE Immunotherapeutics SA
  • 15. Pfizer, Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER IMMUNOTHERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER IMMUNOTHERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROGRAMMED DEATH 1 & PROGRAMMED DEATH LIGAND 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 164. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 180. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 188. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 196. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 213. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 221. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 229. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 237. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 245. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 253. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 261. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 277. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 285. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 293. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 301. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 302. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 309. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 310. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 318. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 326. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 332. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 333. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 334. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 340. SWE